...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study

Re: Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study

posted on Jun 22, 2020 12:02PM

In the past we had a couple day discussion about NASH on this board. There is one poster (maybe Toinv) that is keeping a list of all of the issues, syndromes that RVX is having a positive effect on. I think the last time he posted it there were around 14.

This is fantastic news this morning.

Given DM's comments at the AGM about this now being a big boys game I do believe it will not be long before we hear about a partnership. The details that BDAZ is looking for will likely be guided by any future partner.

My guess on BoM2 study size is 4k to 5k patients, 2 to 3 yrs in length with a Futility Study in the middle for a possible early ending.

What a great morning.

All IMO, DYODD

tada

Share
New Message
Please login to post a reply